MENLO PARK, Calif., Feb. 22, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it will be presenting at the Citi 2012 Global Healthcare Conference and the RBC Capital Markets Healthcare Conference, both in New York City.
The presentation at the Citi conference is scheduled for 8:30 am EST on Tuesday February 28, 2012.
The presentation at the RBC conference is scheduled for 1:30 pm EST on Wednesday February 29, 2012.
Both presentations will be webcast, and the webcasts and presentation slides can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days on the company's website.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529